Three Vietnamese researchers in Hong Kong have solved a 20-year puzzle in molecular biology that could reshape how scientists ...

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "RNA Interference Therapy-Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The "RNA Interference Therapy - Competitive ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will focus ...

Please provide your email address to receive an email when new articles are posted on . Three phase 2 trials demonstrated the efficacy and safety of RNA interference therapy for the treatment of mixed ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly ...

The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial. In such individuals, known to be at ...

(MENAFN- GlobeNewsWire - Nasdaq) RNA interference (RNAi) therapy offers groundbreaking potential to revolutionize disease treatment by targeting gene silencing. Opportunities lie in developing ...